Bone marrow transplant (BMT) is a procedure used for the treatment of a variety of cancers and malignant diseases. Recovery from this intensive process requires a long-term course, often accompanied by acute morbidity which includes various distressing physical symptoms. Recent literature has begun to explore the impact of this procedure on quality of life and psychosocial issues. While survivorship is often associated with a highly rated global quality of life, recovery from BMT is accompanied by several psychosocial difficulties which negatively impact patients. Fatigue is a common complaint, often hindering recipients for several years following their transplant. As well, reports of psychological distress, psychiatric symptoms, and/or mood disturbances such as anxiety or depression are not uncommon. Many patients also indicate interruption of sexual activity and increased sexual difficulty for several months following BMT. While some investigators have begun to examine hormone replacement therapy (HRT) as a treatment option for reducing sexual dysfunction, there is a general paucity of literature evaluating interventions for BMT survivors. This article reviews the literature examining various quality of life aspects including fatigue, psychosocial difficulties, and sexual functioning of patients during recovery from BMT. Limitations of past research are discussed and directions for future research suggested. Keywords: bone marrow transplantation; review; fatigue; sexual functioning; psychological distress Bone marrow transplantation (BMT) is an innovative procedure developed for treating malignant disease. The most common indications for BMT are Hodgkin's disease, nonHodgkin's lymphoma, leukemia, metastatic breast cancer, and its use is increased as treatment technology improves, particularly with respect to reduced morbidity and increased life expectancy. Two types of BMT are currently most Correspondence: CS Neitzert,
prevalent. Allogeneic transplantation uses donor blood and marrow and is most often employed in the treatment of hematological disorders. It may be associated with graftversus-host disease (GVHD), which involves attacks by donor marrow on the patient's organs and can result in serious complications. Autologous transplantation, by contrast, is used to treat several types of malignancies. Because the patient's own marrow is used, there is no GHVD risk. According to data available through the International Bone Marrow Transplant Registry (IBMTR), 4000 allogeneic BMT procedures and 6000 autologous BMT procedures were performed in North America in 1994. The same registry shows that in 1995, 4500 allogeneic BMT procedures and 8000 autologous BMT procedures were performed in North America, suggesting an increasing trend towards use of autologous transplantation where feasible. While the relapse and long-term survival rates for BMT vary with disease type and status, 1 estimates of between 50 and 60% have been projected for patients treated during first remission of leukemia. 1, 2 Our initial review of research literature on BMT suggested that patients experienced a relatively high global quality of life following transplantation. Several investigators found that a majority of patients assessed reported satisfying and productive lives following BMT. [3] [4] [5] [6] [7] [8] For example, Wingard et al 4 (1991) reported that 67% of their mixed autologous, syngeneic and allogeneic sample judged their global health to be good-to-excellent 6 months after BMT, with 65% reporting a return to work. Other reports indicated global improvements in health with increased time following transplant. In a longitudinal study of 58 recipients of autologous BMT, Chao et al 5 (1992) reported that at 90 days post-transplant about one-third of patients reported difficulty sleeping and poor appetite. One year following transplant, only 5% of these subjects reported difficulty sleeping and all reported normal appetites. Furthermore, 78% of this sample were employed at 1-year followup and 88% indicated above average or excellent life satisfaction. Such findings supported positive expectations about BMT recovery.
However, our review of more specific reports indicated that a significant proportion of patients experience ongoing problems following transplantation. Reports of adverse symptoms have consistently cited fatigue, various physical problems, psychological distress, and impaired sexual functioning. More recent research on the quality of life of patients has become increasingly empirically based, with several investigators conducting descriptive and discriminating analyses. While a review of all literature relating to psychosocial issues and BMT is beyond the scope of this paper, we have attempted to provide a thorough and comprehensive examination of the most salient empirical studies pertaining to issues of fatigue, psychological distress and sexual functioning in adult recipients. To locate these articles, we conducted an exhaustive literature search of Medline, PsycLit, CINAHL and Health Star using the following key words or phrases: bone marrow transplantation, sexual functioning, gonadal functioning, endocrinology, fatigue, quality of life, psychological distress. A summary of the most relevant studies and their findings can be found in Table 1 .
Physical symptomatology and fatigue
The physical functioning of cancer patients is often limited by medical symptoms and BMT patients are no exception. [9] [10] [11] [12] In an early cross-sectional investigation, Wolcott et al 13 (1986) evaluated the physical symptomatology of young adult ABMT patients (n = 26), assessed at a mean of 42 months post-treatment. Approximately 25% reported frequent, ongoing physical symptoms including diarrhea, dry mouth and abdominal cramps, and one-third described having a high number of infections within the past year. In a larger cross-sectional study, Haberman and colleagues 14 (1993) used an open-ended questionnaire to collect data on health problems among a sample of 125 BMT survivors, between 6 and 18.4 years post-transplant. A content analysis of their responses revealed a high incidence of sideeffects such as persistent colds, influenza, memory problems, fatigue, shingles, and pain.
Among the symptoms reported, fatigue appears as one of the most common and distressing for cancer patients, with consistent reports of decreased physical abilities, increased need for rest, physical weakness and unusual tiredness. [9] [10] [11] [15] [16] [17] [18] [19] For BMT patients, fatigue appears to be an especially significant and impairing problem. For example, a cross-sectional, descriptive study, conducted by Whedon et al 20 (1995) , indicated that among 29 patients assessed, fatigue was the most frequently reported symptom, with 50% endorsing moderate to severe levels as many as 3 or more years after autologous transplant. These results were confirmed by a larger, multi-center study in which 200 BMT survivors, averaging 41 months post-transplant, were asked to rate their experience of physical symptomatology for both prevalence and severity (during the preceding week). These BMT patients perceived their physical health as significantly poorer than normative standards. Once again, fatigue was found to be the most frequently reported symptom, with 78% of the sample feeling consistently tired. As well, the participants rated fatigue symptoms among their most severe. 21 While these studies have demonstrated that fatigue is a disruptive and limiting symptom following BMT, the majority have been cross-sectional in design. One exception is a recent multi-center investigation which examined the energy level and sleep quality of 172 allogeneic and autologous BMT patients longitudinally, providing data of patient recovery over 5 years post BMT. At the initial assessment conducted 43.5 months post-transplant, 65% of patients indicated a current problem with energy level and 51% endorsed the presence of sleep difficulty. Approximately 30% of these patients rated their problem as moderate or severe. Furthermore, 40% of all participants noticed a decrease in both energy level and sleep quality specifically since receiving their cancer diagnosis. A second assessment with these individuals was conducted 62 months post-transplant, at which time patients reported continued problems with energy level and sleep quality. No significant temporal changes between initial and follow-up assessments were found, suggesting that for many BMT recipients, energy deficits and sleep difficulties remain a problem up to 5 years post-transplant. 22 In another longitudinal investigation, the quality of life of 125 BMT survivors was evaluated a mean of 10 years after transplant. Participants were asked to complete a number of questionnaires with respect to medical complications, psychological distress and health perceptions. Results indicated that BMT survivors continued to have several debilitating physical symptoms 10 years following treatment, with fatigue rated as their second most problematic concern. 8 While several descriptive studies have indicated that BMT recipients frequently complain of fatigue, weakness, decreased energy and insomnia in their long-term recovery from BMT, 4, 8, 13, 14, [20] [21] [22] [23] [24] [25] [26] most have not provided comparisons with normative samples. Two anomalous studies provide valuable insight into the experience of fatigue in BMT survivors. Hann and colleagues 27 compared symptoms among 43 post-BMT females, averaging 20 months since transplant, to 43 healthy control females with no prior cancer history. The BMT survivors showed significantly greater impairment in physical functioning, and reported significantly worse overall physical health. Distressing levels of fatigue were reported by 72% of these BMT survivors, and found to be significantly related to poorer overall physical health. In a similar study, Prieto and colleagues 28 collected cross-sectional data from 117 male and female post-BMT patients, a mean 55 months after transplant. Their analyses indicated that the BMT survivors reported significantly lower energy levels than the normative reference sample.
In summary, research in fatigue has shown that a large proportion of BMT patients are impacted by fatigue as many as 10 years following the procedure. While many early studies were descriptive and cross-sectional in design, similar findings have been replicated in recent analyses which employ normative comparison samples and/or longitudinal designs. However, these data overall are limited in sample size, and by confounding variables such as diagnosis and secondary treatments. Further study with larger samples and comparison to normative control groups are necessary.
Psychological distress
The existing literature on BMT survivors suggests that a significant proportion of patients also experience a high degree of psychological or emotional distress following 24 (1996) evaluated emotional distress in 24 females who had received autologous BMT treatment for breast cancer. They report 33% of their sample had scores above the cut-off for clinical depression on a short-form version of the Center for Epidemiological Studies -Depression Scale (CES-D), when assessed approximately 9 months following treatment. In another small sample (n = 29), Whedon et al 20 (1995) found that as many as 93% reported moderate to severe psychological distress, defined by self-rating on a six-item, open-ended questionnaire administered an average of 37 months following transplant.
Other investigations, using standardized instruments of measurement, have demonstrated significant emotional distress, 13 psychiatric symptoms, 29 and affective disturbances such as anxiety/depression following BMT. [30] [31] [32] [33] [34] [35] [36] For example, a carefully designed prospective study of 67 adult patients undergoing allogeneic BMT treatment evaluated psychosocial functioning at pre-transplant, 90 days post-transplant, and up to 6 years following transplant using the Brief Symptom Inventory (BSI). The results showed that while physical functioning improved significantly at 1-year posttransplant assessment, the elevated anxiety/depression levels found at 90 days post-treatment were sustained. While the overall mean scores were not significantly higher than normative samples, anxiety scores of 48% of the BMT patients and depression scores of 45% of the BMT patients were more than one standard deviation above the normal means. The investigators also noted mild to moderate impairment in physical and/or psychosocial performance among 30-40% of the 23 long-term survivors. 32 In a similar prospective study Leigh et al 34 (1995) assessed 36 adults prior to BMT, 3-5 months following BMT, and again 6-9 months post-transplant. The authors noted that overall 54% of the sample assessed before and at least once after BMT were reporting Hospital Anxiety and Depression Scale (HAD) scores of depression or anxiety above the clinical cut-off. Analyses showed that anxiety levels fluctuated over time with a significant decrease in score noted at the third assessment. In contrast, the authors found that the substantive depressive symptomatology observed in patients remained high up to 9 months post-transplant. Whereas 19% suffered from clinically diagnosed depressive illness at the pre-transplant measure, 31% met criteria at the second assessment, and 19% at the third assessment.
For some BMT survivors, psychological symptoms after transplant can lead to severely dysfunctional states, as in the case studies reported by Molassiotis and Morris 36 (1997). They discuss two reports of attempted suicide following BMT, including one case that evolved into a psychotic episode, and another in which a patient experienced serious suicidal ideation during the period of isolation following transplant. While the authors acknowledge that steroid treatment may have induced the psychotic reaction, they also mention the intense physical limitations experienced by patients as potential factors contributing to severe depression and suicidal ideation. They recommend that all BMT patients be assessed more closely for depressive symptomatology during follow-up appointments.
Although reference samples have been limited, some investigators have compared the psychological status of BMT recipients to normative samples or patients following other cancer treatments. Preliminary results indicate significantly higher levels of mood disturbance, tension and depressive symptoms in BMT patients when compared with lung cancer patients, testicular cancer patients and maintenance chemotherapy patients. 37, 38 An investigation comparing psychological distress following BMT between patients with breast cancer and patients with hematological disorders demonstrated significantly different patterns of response over the course of short-term recovery. 39 While this study only examined patients up to several days following treatment, it provides information regarding the differential responses of disparate diagnostic groups which complicates the interpretation of previous data.
Another study compared the results of 231 allogeneic BMT recipient scores on the Medical Outcomes SurveyShort Form 36 (MOS SF-36) with those of a normative comparison sample. The results indicated that patient scores on five of eight quality of life subscales, including a rating of emotional functioning, were significantly lower than the normative sample. Further analyses determined a distinction in recovery based on time since transplant. Patients who had received BMT within the past 3 years demonstrated significantly lower scores on seven of the eight MOS SF-36 scales, including measures of physical functioning, emotional functioning, social functioning, general health, pain and vitality. Those patients who had received BMT more than 3 years prior to the study were found to have scores significantly higher than the normative population on three subscales (social functioning, vitality and general mental health), and not significantly different from the normative sample on the other five subscales. 26 These results indicate substantial improvement in quality of life and psychological functioning of patients after 3 years or more post-BMT compared with healthy populations. Additional prospective investigations conducted over similar periods of time and using comparison control samples consisting of other cancer groups and healthy individuals need to be conducted to add merit to these observations.
Sexual functioning
In her review of sexual functioning following cancer treatment, Andersen 40 (1990) found that a high percentage of cancer patients experienced some interruption in sexual function, depending on the course of cancer therapy received. Several reports have identified sexual dysfunction during recovery as a common problem among BMT survivors. Baruch et al 31 (1991) studied 46 males who had received BMT treatment for hematological malignancies. Whereas 22% of the patients had reported sexual problems prior to their transplant, 48% stated the presence of some degree of sexual difficulty following treatment. Results of numerous other studies have shown that between 26 and 82% of BMT patients note some degree of sexual dysfunction following transplantation. 5, 7, 8, 24, [41] [42] [43] [44] [45] [46] [47] In a multi-center study, Molassiotis et al 38 (1996) studied 91 adult BMT survivors in comparison with 73 patients with hematological malignancies being treated with maintenance chemotherapy. While the BMT group was assessed at an average 419 of 40 months post-BMT, the maintenance chemotherapy group was evaluated about 39 months after their first chemotherapy treatment. The authors reported significantly higher impotence-related problems among male BMT patients than males who received maintenance chemotherapy treatment. While not significant, the authors also noted a trend among the post-BMT males to report higher levels of sexual dysfunction. The only difference noted among the female participants was with respect to body image, with maintenance chemotherapy females reporting significantly higher concerns.
An earlier study conducted by the same investigators compared sexual functioning in male BMT survivors (36 months post-transplant) with a mixed-diagnostic group of male cancer patients and a group of healthy male controls. Almost half (48%) of the BMT group were dissatisfied with their current sexual life while 38% reported low sexual interest. Twenty-one percent of BMT survivors reported altered body image, 38% had impotence-related problems, including erectile difficulties, and 17% stated they were experiencing moderate difficulties in their overall psychosexual adjustment. While no significant differences were found on sexual functioning variables between cancer groups, psychological distress was found to be significantly higher in the BMT patients, which the authors believed might have impacted their sexual functioning. Both BMT and cancer patients were found to have significantly worse scores on all aspects of sexual functioning, compared to healthy controls, with the exception of sexual desire. 45 In another study evaluating sexual functioning in BMT recipients, Altmaier et al 48 (1991) demonstrated much higher rates of sexual dysfunction in BMT patients relative to patients treated with chemotherapy alone as long as 2 years after treatment. More specifically, BMT patients stated that they experienced decreased desire (42% of patients), decreased sexual functioning (17% of patients), inability to function (25% of patients) and difficulties with their partners over sex (33% of patients). In comparison, while 33% of the chemotherapy group reported decreased desire, none of these patients reported decreased sexual functioning, functional inability or difficulties with their partners over sex.
The reports of BMT patients indicate that they experience a variety of specific problems. In a cross-sectional follow-up study of 36 females treated with BMT, Cust et al 41 (1989) indicated that 6 months following treatment, 92% of the participants reported some experience of disruptive psychosexual symptoms, with 82% reporting pain during intercourse, and 81% experienced vaginal dryness. As well, 64% of these women reported difficulty achieving orgasm, and 73% reported that their desire for sexual activity had significantly decreased since treatment, perhaps in relation to their physical discomfort. In a similar study with both male and female BMT survivors, Vose et al 43 (1992) examined 50 autologous BMT recipients at least 1 year following transplantation. It was noted that 33% of all patients reported decreased interest in sexual activity, while 40% indicated that their sexual functioning remained substantially diminished. Among the male patients, the most commonly reported sexual problems were difficulty achieving erection (reported by 38% of males), and ejaculatory difficulty (reported by 35% of males). Among the female participants, distressing vasomotor symptoms were the most common complaint, with 44% reporting hot flashes.
Taken together, these studies point to a high degree of difficulty with general sexual functioning following BMT therapy. However, many studies have failed to measure baseline (ie pre-treatment) sexual functioning, leaving it difficult to evaluate potential changes in sexual functioning that occur in relation to BMT treatment. Marks et al 49 (1996) found evidence of substantial self-reported sexual dysfunction among 30 patients prior to high-dose chemotherapy or BMT treatment, suggesting that these difficulties arise prior to transplant. However, this study did not provide analysis of post-treatment functioning, eliminating the opportunity to compare pre-and post-assessment impact. Furthermore, little research has been conducted using comparative samples such as healthy controls or cancer groups with varying treatment regimens or diagnoses, and studies are often limited by small sample sizes. Finally, as research on this topic is relatively recent, few studies have investigated sexual functioning longitudinally to determine what changes occur as a function of changes in physical condition.
Endocrine studies
In an effort to understand the physiological and psychosexual changes following BMT, researchers have assessed hormonal responses in long-term survivors. Benker et al 50 (1989) evaluated the growth hormone (GH) and thyroid stimulating hormone (TSH) levels in 23 recovering allogeneic BMT patients and found them to have remained significantly lower than control values between 1 and 6 years following transplant. Substantially lower levels of GH, TSH, estrogen levels, and some decreases in testosterone, accompanied by an increase in both follicle stimulating hormone (FSH) and luteinizing hormone (LH) severely limiting fertility have been reported in other investigations. [51] [52] [53] [54] [55] [56] Although pregnancy has been observed in some cases, 57 its occurrence is rare among patients recovering from BMT.
Few studies evaluating hormonal changes following BMT have been conducted using a prospective design. One such evaluation of adolescent survivors of allogeneic transplant conducted by De Sanctis et al 51 (1991) , compared pre-transplant hormone levels with a post-transplant (mean = 2.3 years following BMT) assessment. Results clearly showed a substantial disruption in hormone levels following BMT relative to pre-treatment values, with females apparently sustaining a greater disturbance than males. It is unclear whether the pre-treatment levels were normative relative to control standards, as this information was not provided. Furthermore, as this study was conducted with adolescents it is unclear whether these results are generalizable to adult BMT patients.
The long-term impact on hormone levels can be substantial, and BMT survivors frequently suffer not only sexual dysfunction but also infertility. In a retrospective review of 1326 patients, 76 women had a total of 146 pregnancies, some of which were in women who had undergone BMT treatment themselves, and some of which were carried by partners of male BMT survivors. Among these individuals, Sanders et al 54 (1996) found a significantly increased rate of pre-term babies and spontaneous abortions compared with the normative standards among healthy women. This team of investigators estimated that as few as 16% of the women in this study had regained normal ovarian functioning.
Hormone replacement therapy
The findings that BMT survivors experience hormonal irregularities have given rise to the use of hormone replacement therapy (HRT) to treat sexual dysfunction in patients, with preliminary evidence demonstrating some benefits. Spinelli et al 58 (1994) prospectively followed 74 adult females undergoing allogeneic BMT over a period of several years. Immediately following treatment all participants were exhibiting evidence of ovarian disruption as a result of changes in their hormonal functioning. Six months after BMT, 94% of the 52 sexually active patients were reporting sexual difficulties which included vaginal dryness, dysuria, dyspareunia, decreased libido and/or decreased activity. To assist these patients, the investigators administered HRT with encouraging results. Of 49 women who received systemic HRT, 81% reported a dramatic improvement in their frequency and enjoyment of sexual activity and a substantial decrease in sexually related physical symptomatology. Cust et al 41 (1991) also administered hormone replacement therapy with apparent success: following BMT, 81% of subjects were experiencing vaginal dryness, 82% reported pain during intercourse, 73% noted decreased libido, and 64% reported difficulty achieving orgasm. By contrast, after 6 months of HRT, 81% of these women reported a substantial reduction in sexual difficulties and an improvement in their activity levels. While the results above suggest HRT may be a viable treatment option for women, there is a distinct absence of research on the benefits of this treatment for male BMT patients.
Limitations of past research and future directions
A number of methodological problems limit the applicability of available research. Many studies have used mixed patient samples, which include individuals who have received autologous and allogeneic forms of BMT, as well as patients who have received total body irradiation (TBI) and those who have not been irradiated. These mixed samples have been used, despite findings indicating significant differences between these groups in terms of treatment characteristics and treatment effects. 21, 38 Past investigations have also grouped together patients who received differing pre-BMT courses of chemotherapy or radiation therapy. Different treatment regimens may be associated with distinctive physical and/or emotional side-effects impacting aspects of the quality of life of patients. As well, longitudinal studies are notably lacking with most investigations being cross-sectional and descriptive in nature. Small sample sizes are also a limitation of past research, with some studies using as few as 12 subjects. As Wingard 59 (1994) notes, study samples have been rarely stratified in terms of demographic variables such as socioeconomic status, age, disease or treatment, further limiting their generalizability to other patient populations. In a recent review of literature on BMT and QOL, Hjermstad and Kaasa 60 (1997) suggest that little detail is known about the specific patterns of experiences during recovery in the first years following BMT. Longitudinal examinations can provide more informed understanding of this process.
Among the studies investigating the specific effects of BMT, there has also been a lack of agreement on standard assessment measures of quality of life, psychological distress, and sexual functioning, making meaningful comparisons between study samples difficult. In particular, global and quality of life assessments have been used interchangeably despite there being considerable differences between these assessment formats. Continued prospective research in functional status, psychosocial adjustment factors, and psychosexual functioning with reliable validated instruments, and more adequate sample sizes are necessary to definitively evaluate the apparent contrasts between global QOL reports and reports of specific types of post-treatment dysfunction and symptomatic distress. One likely explanation for the disparate results lies in appreciation that patients have for the effects of BMT in terms of survival, as it is indeed a life-saving treatment with few alternatives. Clearly, the subjects in these studies have been survivors for whom the treatment has been relatively successful, at least over the short term (the duration of most studies). It is only logical that these patients would be grateful for the treatment and their retained life expectancy, which would be reflected in their global QOL scores. However, it is important not to overlook the less positive reports concerning specific QOL indices. Post-treatment difficulties of BMT patients deserve a significant amount of attention, and indications of distress should not be neglected.
Conclusion
A thorough literature review illustrates a number of functional impairments that patients experience after bone marrow transplantation. In particular, fatigue, psychological distress and sexual dysfunction are reported with high incidence in a number of studies. Clearly, advances in treatment will result in improvements in quality of life and level of functioning for these patients. As previous research has been predominantly descriptive, future emphasis should be placed on prospectively evaluating therapeutic interventions that attempt to improve quality of life. Future research should also continue the examination of impact of BMT on sexual functioning and psychological distress, with particular emphasis on comparisons with healthy controls and other cancer groups. Preliminary results suggest HRT is a viable and beneficial treatment option in reducing sexual disturbances, although research in this area has been limited. Investigations must aim at determining which therapeutic methods help to eliminate debilitating symptoms, thereby enhancing both specific and global indices of quality of life for patients.
